Prior to the outbreak of COVID-19, viral hepatitis was responsible for more fatalities in the United States than the combined total from all other 60 reportable infectious diseases, including HIV, pneumonia, and tuberculosis. This is particularly perplexing given that effective vaccines exist for both hepatitis A and B. Moreover, there are proven treatments available for hepatitis B and a curative therapy for hepatitis C.
In theory, the eradication of viral hepatitis within the U.S. should be feasible; however, contrary to expectations, new instances are escalating primarily due to the opioid crisis which has led to increased transmission through injection drug use.
To combat infectious diseases effectively, public health departments employ a process known as surveillance. This involves the systematic collection and analysis of data concerning the prevalence of a disease, the demographics of affected individuals, and identification of those at heightened risk for infection. Additionally, this data can uncover significant disparities in healthcare access and treatment based on race, ethnicity, age or other demographic factors, emphasizing the need for an ideal healthcare system and robust healthcare policy issues management.
Accurate surveillance data are crucial for developing cost-effective and equitable interventions aimed at both preventing and treating infectious diseases. However, with respect to hepatitis C—a condition estimated to impact up to 4 million individuals in the U.S.—the existing surveillance infrastructure or lack thereof, highlights critical gaps in our healthcare content management system.
A recent study conducted by the HepVu Project at Emory University, in collaboration with NASTAD (the National Alliance of State & Territorial AIDS Directors), reveals a concerning shortfall in the capacity of many public health departments across the United States to gather essential data for assessing the regional and national impact of viral hepatitis infections.
The findings from the HepVu/NASTAD report indicate that approximately 20% of jurisdictions lack dedicated personnel to manage routine surveillance tasks related to viral hepatitis. Furthermore, about one-third of these are unable to produce annual summaries on viral hepatitis surveillance—an essential tool for informing funding allocations—which include preliminary statistics such as prevalence rates within specific cities or states. Alarmingly, only 3% of jurisdictions reported having adequate federal resources to make strides toward eradicating this disease.
Viral hepatitis, especially hepatitis C, disproportionately impacts minority communities, incarcerated individuals, those who inject drugs, people living with HIV/AIDS, individuals experiencing homelessness, and adults over age 60 who may have engaged in high-risk behaviors like injection drug use or received blood transfusions prior to 1992. The absence of comprehensive surveillance systems impedes our understanding of systemic inequities that contribute to infection rates and adverse health outcomes. Such gaps also hinder our ability to monitor epidemiological trends effectively or work towards eliminating viral hepatitis nationwide conclusively.
In 2023, the Biden Administration launched a significant initiative aimed at ending hepatitis C across the United States. This initiative seeks to achieve a 90% reduction in new infections and a 65% decrease in deaths related to viral hepatitis by the year 2030. To attain these national elimination targets and effectively monitor progress at local levels, comprehensive surveillance systems are crucial. However, many jurisdictions may lack the necessary data without adequate funding for such robust surveillance, reflecting the urgent need for improvements in our healthcare storage systems and online health services.
The budget proposal for fiscal year 2025 presented by President Biden requested an allocation of $9.4 billion specifically dedicated to eradicating hepatitis C infections within the nation. This investment is projected to yield over $13 billion in savings for the federal government over a decade, with continued financial benefits thereafter.
Bipartisan efforts led by U.S Senators Chris Van Hollen (D-Md.) and Bill Cassidy (R-La.) are also underway. They are advocating for legislation focused on eliminating viral hepatitis which underscores the necessity of funding a comprehensive viral hepatitis surveillance system. Such infrastructure would empower public health departments to deploy effective interventions, allocate resources strategically and evaluate outcomes efficiently.
Understanding that successful navigation towards these elimination goals depends heavily on clear guidance; robust surveillance systems serve as critical tools facilitating cost-effective, equitable healthcare investments geared towards eradicating viral hepatitis, showcasing the pivotal role of healthcare policy in driving national health initiatives.
